Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:ATXI NASDAQ:KZR NASDAQ:NCNA On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeATXIAvenue Therapeutics$0.30-7.9%$0.40$0.15▼$0.97$988K-0.215,900 shs2,086 shsKZRKezar Life Sciences$7.29$7.16$3.53▼$7.55$53.86M0.4125,152 shs616,000 shsNCNANuCana$1.83-4.2%$2.06$1.33▼$25.58$7.95M2.1846,252 shs27,952 shs(Almost) Everything You Need To Know About The EV MarketLooking to profit from the electric vehicle mega-trend? Click the link to see our list of which EV stocks show the most long-term potential.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceATXIAvenue Therapeutics-7.86%-6.25%+24.53%+3.45%+0.40%KZRKezar Life Sciences0.00%0.00%0.00%+13.73%+61.28%NCNANuCana-4.19%-4.69%-9.41%+15.09%-90.85%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeATXIAvenue Therapeutics$0.30-7.9%$0.40$0.15▼$0.97$988K-0.215,900 shs2,086 shsKZRKezar Life Sciences$7.29$7.16$3.53▼$7.55$53.86M0.4125,152 shs616,000 shsNCNANuCana$1.83-4.2%$2.06$1.33▼$25.58$7.95M2.1846,252 shs27,952 shs(Almost) Everything You Need To Know About The EV MarketLooking to profit from the electric vehicle mega-trend? Click the link to see our list of which EV stocks show the most long-term potential.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceATXIAvenue Therapeutics-7.86%-6.25%+24.53%+3.45%+0.40%KZRKezar Life Sciences0.00%0.00%0.00%+13.73%+61.28%NCNANuCana-4.19%-4.69%-9.41%+15.09%-90.85%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceATXIAvenue Therapeutics 0.00N/AN/AN/AKZRKezar Life Sciences 1.67Reduce$6.00-17.70% DownsideNCNANuCana 1.00SellN/AN/ACurrent Analyst Ratings BreakdownLatest NCNA, KZR, and ATXI Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails5/8/2026KZRKezar Life Sciences Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)4/21/2026NCNANuCana Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (E+)(Data available from 6/22/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookATXIAvenue TherapeuticsN/AN/AN/AN/A$1.92 per shareN/AKZRKezar Life SciencesN/AN/AN/AN/A$9.57 per shareN/ANCNANuCanaN/AN/AN/AN/A$7.71 per shareN/ACompare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateATXIAvenue Therapeutics-$10.38M-$0.530.02N/AN/AN/A-471.57%-296.50%8/10/2026 (Estimated)KZRKezar Life Sciences-$56.03M-$6.17N/AN/AN/AN/A-55.42%-47.87%N/ANCNANuCana-$38.71M-$2.98N/AN/AN/AN/A-153.61%-116.03%8/13/2026 (Estimated)Latest NCNA, KZR, and ATXI EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/15/2026Q1 2026NCNANuCana-$2.6440-$1.25+$1.3940N/AN/AN/A5/11/2026Q1 2026KZRKezar Life Sciences-$0.98-$0.78+$0.20-$0.78$1.00 millionN/A3/27/2026Q4 2025KZRKezar Life Sciences-$1.39-$1.99-$0.60-$1.99$1.67 millionN/ACompare DividendsCompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive GrowthATXIAvenue TherapeuticsN/AN/AN/AN/AN/AKZRKezar Life SciencesN/AN/AN/AN/AN/ANCNANuCanaN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioATXIAvenue TherapeuticsN/A2.702.70KZRKezar Life SciencesN/A11.5211.52NCNANuCanaN/A5.485.48Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipATXIAvenue Therapeutics17.34%KZRKezar Life Sciences67.90%NCNANuCana44.00%Insider OwnershipCompanyInsider OwnershipATXIAvenue Therapeutics8.60%KZRKezar Life Sciences10.40%NCNANuCana31.20%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableATXIAvenue Therapeutics43.30 million2.02 millionNot OptionableKZRKezar Life Sciences607.39 million6.70 millionNot OptionableNCNANuCana304.16 million2.86 millionNot OptionableNCNA, KZR, and ATXI HeadlinesRecent News About These CompaniesNuCana plc Sponsored ADRJune 16, 2026 | edition.cnn.comNuCana Appoints Ian Webster as Chief Financial OfficerJune 1, 2026 | globenewswire.comNuCana Reports First Quarter 2026 Financial Results and Provides Business UpdateMay 14, 2026 | globenewswire.comNuCana Posts 2025 Results, Highlights NUC-7738 Progress and Cash Runway Into 2029March 22, 2026 | theglobeandmail.comNuCana Reports Fourth Quarter and Year-End 2025 Financial Results and Provides Business UpdateMarch 19, 2026 | globenewswire.comNuCana plc: NuCana Appoints Theresa Bruce as Chief Operating OfficerJanuary 6, 2026 | finanznachrichten.deNuCana appoints Bruce as COOJanuary 6, 2026 | msn.comNuCana Appoints Theresa Bruce as Chief Operating OfficerJanuary 6, 2026 | globenewswire.comNuCana announces return of CEO Hugh S Griffith following health leaveDecember 17, 2025 | msn.comNuCana Presents Latest Data Demonstrating Clinical Activity and Favorable Safety for NUC-7738 ...December 10, 2025 | bakersfield.comBNuCana presents latest clinical data at ESMO 2025 on NUC-7738December 10, 2025 | msn.comNuCana Presents Latest Data Demonstrating Clinical Activity and Favorable Safety for NUC-7738 in Patients with PD-1-Resistant MelanomaDecember 10, 2025 | globenewswire.comNuCana Reports Q3 2025 Financial Results and Board ResignationNovember 13, 2025 | msn.comNuCana plc: NuCana Reports Third Quarter 2025 Financial Results and Provides Business UpdateNovember 13, 2025 | finanznachrichten.deNuCana Reports Third Quarter 2025 Financial Results and Provides Business UpdateNovember 13, 2025 | globenewswire.comNuCana stock rises after securing key patent in China for cancer drugNovember 5, 2025 | za.investing.comNuCana Shares Climb After Securing Key Chinese Patent for Cancer Drug NUC-7738November 5, 2025 | msn.comNuCana Announces Grant of Composition-of-Matter Patent for NUC-7738 in ChinaNovember 5, 2025 | globenewswire.comNuCana presents data at ESMO 2025 for NUC-7738, PD-1 inhibitorsOctober 19, 2025 | msn.comNuCana Presents Encouraging Data on NUC-7738 in Combination with PD-1 Inhibitors using Primary Patient-Derived Organoids and Autologous Tumor-Infiltrating Lymphocytes at the ...October 18, 2025 | finance.yahoo.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeNCNA, KZR, and ATXI Company DescriptionsAvenue Therapeutics NASDAQ:ATXI$0.30 -0.03 (-7.86%) As of 06/22/2026 02:42 PM EasternAvenue Therapeutics, Inc., a specialty pharmaceutical company, focuses on the development and commercialization of therapies for the treatment of neurologic diseases. Its product candidates include AJ201, which is in a Phase 1b/2a clinical trial for the treatment of spinal and bulbar muscular atrophy; intravenous tramadol for the treatment of post-operative acute pain; and BAER-101 for the treatment of epilepsy and panic disorders. The company was incorporated in 2015 and is based in Bay Harbor Islands, Florida.Kezar Life Sciences NASDAQ:KZRKezar Life Sciences, Inc., a clinical-stage biotechnology company, engages in the discovery and development of novel small molecule therapeutics to treat unmet needs in immune-mediated diseases and cancer in the United States. The company's lead product candidate is zetomipzomib (KZR-616), a selective immunoproteasome inhibitor that is in Phase 2b clinical trials for various indications, including lupus nephritis, dermatomyositis, and polymyositis; Phase 1b clinical trials in systemic lupus erythematosus; and completed Phase 2a clinical trials in lupus nephritis. Its preclinical products include KZR-261, a novel first-in-class protein secretion inhibitor for the treatment of tumors resistant to traditional chemotherapeutics. Kezar Life Sciences, Inc. was incorporated in 2015 and is headquartered in South San Francisco, California.NuCana NASDAQ:NCNA$1.83 -0.08 (-4.19%) Closing price 06/22/2026 04:00 PM EasternExtended Trading$1.84 +0.00 (+0.27%) As of 06/22/2026 07:59 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.NuCana plc, a clinical-stage biopharmaceutical company, engages in the development of medicines to treat patients with cancer. It applies its ProTide technology to transform prescribed chemotherapy agents and nucleoside analogs into medicines. The company, through its technology, is developing ProTides medicines to overcome the limitations of nucleoside analogs and generate much higher concentrations of anti-cancer metabolites in cancer cells. Its pipeline includes NUC-3373, a chemical entity derived from the nucleoside analog 5-fluorouracil that is in Phase 1b/2 study in patients with metastatic colorectal cancer, Phase 2 clinical trial for the second-line treatment of patients with advanced colorectal cancer, and Phase 1b/2 modular clinical trial for patients with advanced solid tumors and lung cancer. It is also developing NUC-7738, a ProTide transformation of 3'-deoxyadenosine, which is in the Phase 2 part of a Phase 1/2 clinical trial for patients with advanced solid tumors. The company has an assignment, license, and collaboration agreement with Cardiff ProTides Ltd to discover, drug design, and in vitro screen purine and pyrimidine-based nucleosides as potential drug candidates. The company was formerly known as NuCana BioMed Limited and changed its name to NuCana plc in August 2017. NuCana plc was incorporated in 1997 and is headquartered in Edinburgh, the United Kingdom. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSilverSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Buy CrowdStrike Before the Stock Split? Here's the Case USA Today's Digital Revival Is Gaining Steam, But With Plenty of Risk Burlington Is Winning Over Shoppers But Investors Need Patience Investors Are Buying Into Sweetgreen Again—Should They? MarketBeat Week in Review – 06/15 - 06/19 Cheesecake Factory Stock Is Up Over 50%—Is There Room for More CAKE? Applied Materials Stock Looks Pricey—Can AI Demand Justify the Rally? Satellogic Is Tiny But Its Revenue Growth Is Hard to Ignore Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
